SCHEMBL4796176

SCHEMBL4796176

CNC(=O)c1ccccc1-c1cc2c(cc1F)C=Cc1ccc(Cl)cc1N(C(C)=O)C2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B3 P37058 14/20 0.54
CHRM2 P08172 1/20 0.38
CHRM4 P08173 1/20 0.38
CHRM5 P08912 1/20 0.38
CHRM1 P11229 1/20 0.38
CHRM3 P20309 1/20 0.38
NOTUM Q6P988 1/20 0.36
GAA P10253 1/20 0.36
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
MAPT P10636 1/20 0.35
ALOX15 P16050 1/20 0.35
CYP2C19 P33261 1/20 0.35
THPO P40225 1/20 0.35
PMP22 Q01453 1/20 0.35
KMT2A Q03164 1/20 0.35
ALOX5AP P20292 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4796170 1.00 HSD17B3 (0.54) HSD17B3CHRM2CHRM4CHRM5CHRM1
SCHEMBL4801463 0.93 HSD17B3 (0.56) HSD17B3CHRM2CHRM4CHRM5CHRM1
SCHEMBL4801450 0.93 HSD17B3 (0.56) HSD17B3CHRM2CHRM4CHRM5CHRM1
SCHEMBL4799399 0.90 HSD17B3 (0.51) HSD17B3CHRM2CHRM4CHRM5CHRM1
SCHEMBL4799413 0.90 HSD17B3 (0.51) HSD17B3CHRM2CHRM4CHRM5CHRM1
SCHEMBL4800132 0.89 HSD17B3 (0.46) HSD17B3NOTUMGAAALOX5APFEN1
SCHEMBL4800142 0.89 HSD17B3 (0.46) HSD17B3NOTUMGAAALOX5APFEN1
SCHEMBL4801178 0.85 HSD17B3 (0.41) HSD17B3GAAALDH1A1CYP2D6MAPT
SCHEMBL4801187 0.85 HSD17B3 (0.41) HSD17B3GAAALDH1A1CYP2D6MAPT
SCHEMBL4803471 0.85 HSD17B3 (0.69) HSD17B3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7417040-B2 Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 BRISTOL-MYERS SQUIBB COMPANY (US) 2008-08-26 US disclosed
US-20050250753-A1 Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 BRISTOL-MYERS SQUIBB COMPANY 2005-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050250753-A1 Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 HSD17B3, HSD17B11, HSD17B1 HSD17B3 1/4885CHRM2 4776/4885CHRM4 4757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.